Search Results
Feb 04, 2026, 17:53 ET Itaú Unibanco - Material Fact: Stock Buyback Program
value and intermediated by Itaú Corretora de Valores S.A.Gustavo Lopes RodriguesInvestor Relations OfficerAttachment G to CVM Resolution No. 80/22Trading of Own Shares1. Justify in detail the purpose and expected economic effects expected from the
More news about: Itaú Unibanco Holding S.A.
Jan 28, 2026, 08:37 ET Azul Announces Offering of Debt Securities and Update its Credit Rating Report
AZUL53, OTC: AZULQ) ("Azul" or "Company"), in compliance with Resolution No. 44 of the Brazilian Securities Commission ("CVM"), dated August 23, 2021 ("CVM Resolution 44"), and article 157, paragraph 4, of Law No. 6,404, dated December 15, 1976 ("Brazilian Corporations Law"),
More news about: Azul S.A.
Jan 20, 2026, 09:00 ET Gauge Capital Announces Strategic Growth Investment in Ecosystems
Ecosystems (the "Company") to provide growth capital and recapitalize the Company. Founded in 2010, Ecosystems pioneered the Customer Value Management (CVM) category and now supports the go-to-market success of world-class B2B leaders, including HP, ServiceNow, Atlassian, and Appian.
More news about: Gauge Capital
Dec 11, 2025, 08:32 ET Gerosynth Labs Announces Investigational New Animal Drug (INAD) Acceptances Spanning Equine, Feline, and Canine Oncology
Veterinary Medicine (CVM) has accepted multiple Investigational New Animal Drug (INAD) files for the company's lead oncology candidates across equine, feline, and canine categories. Each file was additionally granted a Minor Use and Minor Species (MUMS) Animal Health Act designation, the CVM equivalent of
More news about: Gerosynth Labs, Inc.
Dec 09, 2025, 19:26 ET Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody
general biomedicine pipeline reflects a well-structured, echeloned and matrix-like strategy across the fields of cardiovascular and metabolic diseases (CVM), autoimmune diseases, and ophthalmology. For gout, a metabolic and immune-related condition, IB3011 complements the promising Phase 2 clinical results
More news about: Innovent Biologics
Dec 06, 2025, 22:40 ET Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
oncology (including lung, liver, gastric, esophageal, gynecological cancers, and hematological malignancies) as well as cardiovascular and metabolic (CVM) diseases. Their inclusion will help broaden patients' access to and enhance their affordability of these medications, ultimately benefiting more individuals
More news about: Innovent Biologics
Nov 28, 2025, 04:06 ET China's First Domestic IL-23p19 Monoclonal Antibody: Innovent's PECONDLE® (Picankibart Injection) Received NMPA Approval
disease recurrence. Innovent will continue to expand its innovative portfolio in ophthalmology, autoimmune diseases, and cardiovascular and metabolic (CVM) conditions, with the aim to help more people achieve healthier lives."
More news about: Innovent Biologics
Nov 27, 2025, 01:34 ET Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M
Frontiers in Pharmacology journal, Innocan continues to advance the pre-clinical development of LPT-CBD to support compliance with both the FDA and the CVM requirements for development.Preliminary pharmacokinetic and safety evaluations of LPT-CBD in minipigs, provide encouraging support for Innocan's
More news about: Innocan Pharma Corporation
Nov 27, 2025, 01:34 ET Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M
Frontiers in Pharmacology journal, Innocan continues to advance the pre-clinical development of LPT-CBD to support compliance with both the FDA and the CVM requirements for development.Preliminary pharmacokinetic and safety evaluations of LPT-CBD in minipigs, provide encouraging support for Innocan's
More news about: Innocan Pharma Corporation
Nov 25, 2025, 04:00 ET Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population
levels of disease severity. Innovent will continue to strategically build our next-generation product pipeline in the cardiovascular and metabolic (CVM) field, and help people's pursuit of a healthy life."About Mazdutide Innovent entered into an exclusive license agreement with Eli
More news about: Innovent Biologics
Nov 19, 2025, 19:00 ET Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints
evidence and unmet medical needs. Innovent will continue to strategically build our next-generation product pipeline in the cardiovascular and metabolic (CVM) field, and help people's pursuit of a healthy life." Mazdutide has
More news about: Innovent Biologics
Nov 10, 2025, 16:07 ET Rede Mater Dei de Saúde apresenta resultados do 3T/25, registrando crescimento de 16% na Receita e 39% no EBITDA, comparados com o mesmo período do ano passado
períodos", ressalta o CFO da Rede Mater Dei, Rafael Cordeiro. O balanço completo está disponível na Comissão de Valores Mobiliários (CVM) e no site de Relações com Investidores da Mater Dei: ri.materdei.com.br.
More news about: Rede Mater Dei de Saúde
Nov 10, 2025, 09:04 ET FDA Completes Safety for Gallant's First Ready-to-Use Stem Cell Therapy for Refractory FCGS
its lead therapy targeting refractory feline chronic gingivostomatitis (FCGS). The U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) has issued a "Technical Section Complete" letter for Target Animal Safety (TAS), determining that Gallant's data support the 365-day safety requirement
More news about: Gallant
Nov 06, 2025, 22:49 ET Material Fact: Approval of "equity swap" derivative contracts
informs its shareholders and the market that its Board of Directors, in a meeting held on November 6, 2025, according to the minutes published on the CVM and Investor Relations websites, approved the execution by the Company, with Banco Itaú Unibanco S.A., of derivative agreements of "Equity Swap", referenced
More news about: Embraer S.A.
Nov 06, 2025, 20:12 ET Material Fact of Share Buyback Program
December 15, 1976, as amended ("Brazilian Corporate Law"), as well as under Resolution No. 44 of August 23, 2021, as amended, and Resolution CVM No. 77 of March 29, 2022 ("CVM Resolution 77"), informs its shareholders and the market in general that the Board of Directors, in a meeting held on this date, November
More news about: Embraer S.A.
Nov 04, 2025, 17:44 ET ITAÚ UNIBANCO - MATERIAL FACT - Projections 2025
compliance with the provisions of Article 157, paragraph 4 of Law No. 6,404/76 and Resolution No. 44/21 of the Brazilian Securities and Exchange Commission (CVM), informs its stockholders and the market in general that it released as of this date its revised projection for the year 2025 in accordance with item
More news about: Itaú Unibanco Holding S.A.
Oct 30, 2025, 17:53 ET GERDAU S.A. - CONSOLIDATED INFORMATION
GGB, BM&Fbovespa: GGBR3, GGBR4) informs that it is filling today its 3Q25 results at the Securities and Exchange Commission (SEC) and at the Comissão de Valores Mobiliários (CVM), which are available at Gerdau's website. To access this document, please click on:
More news about: Gerdau S.A.
Oct 30, 2025, 17:53 ET GERDAU S.A. - INFORMAÇÕES CONSOLIDADAS
arquivando hoje o documento contendo os Resultados do 3T25 na Securities and Exchange Commission (SEC) e na Comissão de Valores Mobiliários (CVM) e se encontra disponível em nosso site. Para acessar o referido documento clique em:
More news about: Gerdau S.A.
Oct 28, 2025, 13:26 ET Points East Veterinary Specialty Hospital Adds Internal Medicine Service Led by Dr. Claire Wiley
Wiley moved to North Carolina to pursue an internal medicine residency program at North Carolina State University College of Veterinary Medicine. At NCSU-CVM, Dr. Wiley's medical research focused on molecular diagnostics for early cancer detection and canine genetic diseases. Her published work includes
More news about: Vets Pets
Oct 24, 2025, 09:00 ET Indústria de FIDCs cresce 125% desde 2022 e ganha protagonismo em cenário de juros altos, destaca ANFIDC
técnicos qualificados junto à CVM, ao Banco Central e ao governo", afirmou Klever. Regulação e tributação no radar A ANFIDC reconheceu o papel da Comissão de Valores Mobiliários (CVM) na modernização do marco regulatório
More news about: Encontro Nacional da Associação Brasileira das Entidades de FIDC (ANFIDC)
Oct 13, 2025, 22:45 ET Incorporação da GLAI e GIB pela GLA e consequente deslistagem do Nível 2
de São Paulo, Estado de São Paulo, CEP 04719-002), bem como nos websites da Companhia (ri.voegol.com.br), da CVM (www.gov.br/cvm) e da B3 (www.b3.com.br).
More news about: GOL Linhas Aéreas Inteligentes S.A.
Oct 13, 2025, 22:37 ET Incorporation of GLAI and GIB into GLA and future delisting from Level 2
Paulo, State of São Paulo, ZIP Code 04719-002), as well as on the websites of the Company (ri.voegol.com.br), the CVM (www.gov.br/cvm), and B3 (www.b3.com.br).
More news about: GOL Linhas Aéreas Inteligentes S.A.
Sep 30, 2025, 17:22 ET SUPPLE Launches SUPPLE PETS® -- The World's First Supple Hip & Joint Care Chews for Dogs with Premium Human-Grade Chondroitin and Glucosamine at Clinically Effective Dosages
testing – third-party verified for quality and purity. Made in the USA with select global ingredients, consistent with FDA CVM guidelines. This is the same science that has earned Supple ingredients the trust of millions of people
More news about: Supple LLC
Sep 23, 2025, 08:47 ET Gallant Achieves FDA "Technical Section Complete" for Reasonable Expectation of Effectiveness, Advancing First Ready-to-Use Stem Cell Therapy
therapy for cats with refractory feline chronic gingivostomatitis (FCGS).The U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) agreed that Gallant's data provides a reasonable expectation of effectiveness (RXE), a key requirement in the conditional approval process.RXE
More news about: Gallant
Sep 15, 2025, 21:00 ET Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025
pipelines of Innovent Biologics demonstrate a well-established, echeloned and matrix-like layout across the fields of cardiovascular and metabolic diseases (CVM), autoimmune diseases, and ophthalmology. Specifically, in the field of autoimmune diseases, our cornerstone product, picankibart (an anti-IL-23p19 monoclonal
More news about: Innovent Biologics